BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2015 10:26:00 AM | Browse: 1459 | Download: 2726
Publication Name World Journal of Clinical Oncology
Manuscript ID 17648
Country United States
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Randomized Controlled Trial
Article Title Randomized phase Ⅱ trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck
Manuscript Source Unsolicited Manuscript
All Author List Michael Mix, Anurag K Singh, Michael Tills, Shiva Dibaj, Adrienne Groman, Wainwright Jaggernauth, Youcef Rustum and Michael B Jameson
Funding Agency and Grant Number
Funding Agency Grant Number
Health Research Council of New Zealand (In part)
Corresponding Author Anurag K Singh, MD, Professor of Medicine, Radiation Medicine Residency Program Director, University at Buffalo School of Medicine, Professor of Oncology, Director of Radiation Research, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States. anurag.singh@roswellpark.org
Key Words Selenium; Chemotherapy; Radiation therapy; Squamous cell cancer; Radioprotector; Chemoprotective
Core Tip This is an international, randomized, double-blind, placebo-controlled phase Ⅱ trial evaluating the addition of selenomethionine (SLM) to concurrent chemoradiation for locally advanced squamous cell carcinoma of the head and neck. The addition of SLM was well tolerated, but did not lead to a difference in the rates of mucositis, or quality of life outcomes vs placebo.
Publish Date 2015-10-13 10:26
Citation Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB. Randomized phase Ⅱ trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J Clin Oncol 2015; 6(5): 166-173
URL http://www.wjgnet.com/2218-4333/full/v6/i5/166.htm
DOI http://dx.doi.org/10.5306/wjco.v6.i5.166
Full Article (PDF) WJCO-6-166.pdf
Full Article (Word) WJCO-6-166.doc